FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702873> ?p ?o ?g. }

• W4385702873 endingPage "e9811951" @default.
• W4385702873 startingPage "e9811951" @default.
• W4385702873 abstract "Topic: 33. Bleeding disorders (congenital and acquired) Background: Orelabrutinib is an oral, highly-selective, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Orelabrutinib has been approved for the treatment of B cell malignancies in China. Preclinical study showed that orelabrutinib suppressed the activation and differentiation of B cells, and increased the platelet count in active Immune Thrombocytopenia (ITP) murine models. Aims: This ongoing randomized, open-label phase II study is aiming to evaluate the efficacy, safety and tolerability of orelabrutinib in patients with persistent or chronic primary ITP. Methods: Eligible patients who did not respond to or relapsed after or could not tolerate first-line therapy including glucocorticoids (GC) or intravenous immunoglobulin (IVIG) were randomized 1:1 to receive oral orelabrutinib 50mg or 30mg once daily for 24 weeks. If the platelet count was lower than 50×109/L without safety issue at Week 4, intra-patient daily dose escalation from 30mg to 50mg was allowed. The primary endpoint was the percentage of patients who achieved at least two consecutive platelet counts ≥50x109/L without rescue medication in the 4 weeks before the elevated platelet count. Results: As of cut-off date on 6 Feb 2023, 33 patients were randomized to 50mg arm (n=15) and 30mg arm (n=18), respectively with median treatment time of 13.7 weeks (range, 2.9-50.1). Among the 30mg arm, 12 patients were transferred from 30mg to 50mg after Week 4 due to no primary response. At baseline, the mean age was 41.9 years and 63.6% were female. The mean platelet count was 13.4±10.54x109/L and patients had received a median of 5 different prior ITP therapies (range, 1-12) with mean disease duration of 8.2 years. Overall 36.4% (12/33) patients met the primary endpoint, 40% (6/15) at the 50mg arm, 22.2% (4/18) at the 30mg arm, and 2 patients reached primary endpoint after transferring to 50mg. Total 27.3% (9/33) patients achieved durable response defined as the percentage of patients with platelet count ≥50x109/L for at least 4 of the 6 visits between 14-24 weeks without rescue medication within 4 weeks before the elevated platelet count. The data from 22 patients with previous response to GC or IVIG were analyzed as a sub-group: 75.0% (6/8) at the 50mg arm and 28.6% (4/14) at the 30mg arm achieved the primary endpoint. The durable response rate was 50% (4/8) at the 50mg arm and 21.4% (3/14) at the 30mg arm, respectively. Among 12 patients with primary endpoint response, 81.8% (9/11) patients achieved durable response and 1 patient who received only 8 weeks treatment by cutoff but had 8 consecutive platelet counts≥50x109/L. The median time to the first platelet count of ≥50x109/L was 9.0 days (range, 7-156) with initial 50mg dose, and 43.0 days (range, 7-128) with initial 30mg dose. A total of 28.1% of patients experienced at least one treatment related adverts events (TRAE), all of which were grade 1 or 2. There was no treatment-related bleeding or thrombotic events. No grade 3 or higher TRAE, serious TRAE and death were reported. There was no TRAE leading to drug discontinuation. Summary/Conclusion: Both 50mg QD and 30mg QD of orelabrutinib were safe in the treatment of patients with ITP. Generally, orelabrutinib 50mg QD responded rapidly with better efficacy, especially in those who had responded to previous GC/IVIG therapies. Figure:Keywords: B cell, Platelet count, Immune thrombocytopenia (ITP), Treatment" @default.
• W4385702873 created "2023-08-10" @default.
• W4385702873 creator A5002661071 @default.
• W4385702873 creator A5019751079 @default.
• W4385702873 creator A5020499803 @default.
• W4385702873 creator A5023342846 @default.
• W4385702873 creator A5033900220 @default.
• W4385702873 creator A5047414727 @default.
• W4385702873 creator A5048815633 @default.
• W4385702873 creator A5066047367 @default.
• W4385702873 creator A5069603616 @default.
• W4385702873 creator A5079749941 @default.
• W4385702873 creator A5083531621 @default.
• W4385702873 creator A5090567341 @default.
• W4385702873 creator A5091815974 @default.
• W4385702873 date "2023-08-01" @default.
• W4385702873 modified "2023-09-23" @default.
• W4385702873 title "S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY" @default.
• W4385702873 doi "https://doi.org/10.1097/01.hs9.0000968108.98119.51" @default.
• W4385702873 hasPublicationYear "2023" @default.
• W4385702873 type Work @default.
• W4385702873 citedByCount "0" @default.
• W4385702873 crossrefType "journal-article" @default.
• W4385702873 hasAuthorship W4385702873A5002661071 @default.
• W4385702873 hasAuthorship W4385702873A5019751079 @default.
• W4385702873 hasAuthorship W4385702873A5020499803 @default.
• W4385702873 hasAuthorship W4385702873A5023342846 @default.
• W4385702873 hasAuthorship W4385702873A5033900220 @default.
• W4385702873 hasAuthorship W4385702873A5047414727 @default.
• W4385702873 hasAuthorship W4385702873A5048815633 @default.
• W4385702873 hasAuthorship W4385702873A5066047367 @default.
• W4385702873 hasAuthorship W4385702873A5069603616 @default.
• W4385702873 hasAuthorship W4385702873A5079749941 @default.
• W4385702873 hasAuthorship W4385702873A5083531621 @default.
• W4385702873 hasAuthorship W4385702873A5090567341 @default.
• W4385702873 hasAuthorship W4385702873A5091815974 @default.
• W4385702873 hasBestOaLocation W43857028731 @default.
• W4385702873 hasConcept C126322002 @default.
• W4385702873 hasConcept C168563851 @default.
• W4385702873 hasConcept C197934379 @default.
• W4385702873 hasConcept C203092338 @default.
• W4385702873 hasConcept C2778375690 @default.
• W4385702873 hasConcept C2993327898 @default.
• W4385702873 hasConcept C3019800554 @default.
• W4385702873 hasConcept C71924100 @default.
• W4385702873 hasConcept C89560881 @default.
• W4385702873 hasConcept C90924648 @default.
• W4385702873 hasConceptScore W4385702873C126322002 @default.
• W4385702873 hasConceptScore W4385702873C168563851 @default.
• W4385702873 hasConceptScore W4385702873C197934379 @default.
• W4385702873 hasConceptScore W4385702873C203092338 @default.
• W4385702873 hasConceptScore W4385702873C2778375690 @default.
• W4385702873 hasConceptScore W4385702873C2993327898 @default.
• W4385702873 hasConceptScore W4385702873C3019800554 @default.
• W4385702873 hasConceptScore W4385702873C71924100 @default.
• W4385702873 hasConceptScore W4385702873C89560881 @default.
• W4385702873 hasConceptScore W4385702873C90924648 @default.
• W4385702873 hasIssue "S3" @default.
• W4385702873 hasLocation W43857028731 @default.
• W4385702873 hasLocation W43857028732 @default.
• W4385702873 hasOpenAccess W4385702873 @default.
• W4385702873 hasPrimaryLocation W43857028731 @default.
• W4385702873 hasRelatedWork W1761397256 @default.
• W4385702873 hasRelatedWork W2053485995 @default.
• W4385702873 hasRelatedWork W2087016115 @default.
• W4385702873 hasRelatedWork W2222828401 @default.
• W4385702873 hasRelatedWork W2438976023 @default.
• W4385702873 hasRelatedWork W3112648508 @default.
• W4385702873 hasRelatedWork W3158058762 @default.
• W4385702873 hasRelatedWork W3212096909 @default.
• W4385702873 hasRelatedWork W4304479650 @default.
• W4385702873 hasRelatedWork W4384922324 @default.
• W4385702873 hasVolume "7" @default.
• W4385702873 isParatext "false" @default.
• W4385702873 isRetracted "false" @default.
• W4385702873 workType "article" @default.